2015
DOI: 10.1016/j.jaci.2015.01.039
|View full text |Cite
|
Sign up to set email alerts
|

Control of immunopathology during chikungunya virus infection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
51
0
6

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 61 publications
(57 citation statements)
references
References 86 publications
0
51
0
6
Order By: Relevance
“…CHIKV has been reported in many countries in Asia, America, and Africa after an epidemiologic silent period as a neglected tropical disease (2). The reemergence of CHIKV as an urban epidemic was described in Kinshasa, Democratic Republic of the Congo, in 2000 (15).…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…CHIKV has been reported in many countries in Asia, America, and Africa after an epidemiologic silent period as a neglected tropical disease (2). The reemergence of CHIKV as an urban epidemic was described in Kinshasa, Democratic Republic of the Congo, in 2000 (15).…”
Section: Discussionmentioning
confidence: 99%
“…The Pan American Health Organization recorded 776,000 cases and 152 deaths attributed to CHIKV infection in 33 countries in 2014 (http://www.paho.org/chikungunya). CHIKV infection has been identified in nearly 80 countries across 5 continents and caused more than 6 million confirmed cases (2). While CHIKV imported cases into Northern Italy were very low between 2011 and 2013, the number of imported cases has increased significantly since 2014 (16).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The current understanding of protective immune responses to CHIKV infection has been derived from animal models as well as limited human data following natural infection [11]. The humoral immune response seems to play a more important role in controlling CHIKV infection than cell mediated immunity (CMI).…”
Section: Biological Feasibility For Vaccine Developmentmentioning
confidence: 99%